FY2022 EPS Estimates for Merck & Co., Inc. (NYSE:MRK) Lifted by Analyst

Merck & Co., Inc. (NYSE:MRKGet Rating) – Analysts at SVB Leerink lifted their FY2022 earnings per share estimates for Merck & Co., Inc. in a report released on Friday, April 29th. SVB Leerink analyst D. Graybosch now anticipates that the company will post earnings per share of $7.30 for the year, up from their prior estimate of $7.18. SVB Leerink currently has a “Outperform” rating and a $97.00 target price on the stock. SVB Leerink also issued estimates for Merck & Co., Inc.’s Q1 2023 earnings at $1.54 EPS, Q2 2023 earnings at $1.63 EPS, Q3 2023 earnings at $1.65 EPS and Q4 2023 earnings at $1.74 EPS.

MRK has been the subject of a number of other reports. Barclays increased their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. JPMorgan Chase & Co. decreased their price target on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research note on Friday, January 28th. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price target for the company. StockNews.com started coverage on shares of Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. Finally, Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $90.69.

MRK stock opened at $88.69 on Monday. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $91.40. The company has a market cap of $224.19 billion, a P/E ratio of 15.87, a PEG ratio of 1.24 and a beta of 0.45. The firm has a 50-day moving average of $81.53 and a 200 day moving average of $80.12. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.27 and a quick ratio of 1.02.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same period in the prior year, the business posted $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 31.6% on a year-over-year basis.

Several large investors have recently bought and sold shares of MRK. Norges Bank acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $1,823,028,000. BlackRock Inc. boosted its stake in shares of Merck & Co., Inc. by 5.5% in the fourth quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock valued at $15,191,909,000 after purchasing an additional 10,326,974 shares during the period. Invesco Ltd. boosted its stake in shares of Merck & Co., Inc. by 41.3% in the third quarter. Invesco Ltd. now owns 19,461,290 shares of the company’s stock valued at $1,461,738,000 after purchasing an additional 5,687,973 shares during the period. Geode Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 12.7% in the fourth quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company’s stock valued at $3,682,009,000 after purchasing an additional 5,409,154 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Merck & Co., Inc. by 17.1% in the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after purchasing an additional 3,832,086 shares during the period. 72.05% of the stock is currently owned by hedge funds and other institutional investors.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.